Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first, do no harm

被引：1
|
作者：
Chiva, Luis [1 ]
Vergote, Ignace [2 ]
机构：
[1] Clin Univ Navarra, Dept Ginecol & Obstet, Madrid, Spain
[2] Katholieke Univ Leuven, Leuven Canc Inst, Dept Gynecol & Obstet, Gynecol Oncol, Leuven, Belgium
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / 01期
关键词：
Ovarian Cancer; Surgery; Medical Oncology;
D O I：
10.1136/ijgc-2023-005148
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：10 / 11
页数：2
相关论文
共 50 条
  • [21] Hyperthermic intraperitoneal chemotherapy in ovarian cancer: rationale and clinical data
    de Bree, Eelco
    Helm, C. William
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (07) : 895 - 911
  • [22] Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer
    Vos, Laura M. C.
    Aronson, S. Lot
    van Driel, Willemien J.
    Huitema, Alwin D. R.
    van Leeuwen, Jules H. Schagen
    Lok, Christine A. R.
    Sonke, Gabe S.
    BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2022, 78 : 86 - 102
  • [23] Pharmacological considerations regarding intraoperative hyperthermic intraperitoneal chemotherapy for ovarian cancer
    de Bree, Eelco
    Michelakis, Dimosthenis
    Polioudaki, Hara
    Anagnostopoulou, Elisabeth
    Theodoropoulos, Panayiotis A.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2021, 42 (05) : 1018 - 1028
  • [24] Past, Present, and Future of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer
    Mishra, Mona
    Singh, Nilanchali
    Ghatage, Prafull
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (06)
  • [25] Hyperthermic intraperitoneal chemotherapy does not improve survival in advanced ovarian cancer
    Vergote, Ignace
    Harter, Philipp
    Chiva, Luis
    CANCER, 2019, 125 : 4594 - 4597
  • [26] Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for ovarian cancer: World experience
    Helm, C. William
    Intraperitoneal Cancer Therapy, 2007, : 147 - 161
  • [27] Assessment of travel distance for hyperthermic intraperitoneal chemotherapy in women with ovarian cancer
    Chambers, Laura M.
    Yao, Meng
    Morton, Molly
    Gruner, Morgan
    Chichura, Anna
    Costales, Anthony B.
    Horowitz, Max
    Rose, Peter G.
    Michener, Chad M.
    Debernardo, Robert
    GYNECOLOGIC ONCOLOGY REPORTS, 2022, 40
  • [28] Saved by the evidence: Hyperthermic intraperitoneal chemotherapy still has a role to play in ovarian cancer
    Lavoue, Vincent
    Bakrin, Naoual
    Bolze, Pierre Adrien
    Bendifallah, Sofiane
    Collinet, Pierre
    Graesslin, Olivier
    Ballester, Marcos
    Akladios, Cherif
    Carcopino, Xavier
    Bricou, Alexandre
    Koskas, Martin
    Canlorbe, Geoffroy
    Coutant, Charles
    Ouldamer, Lobna
    Darai, Emile
    Touboul, Cyril
    Huchon, Cyrille
    EJSO, 2019, 45 (10): : 1757 - 1759
  • [29] Hyperthermic intraperitoneal chemotherapy for the treatment of recurrent ovarian cancer in elderly women
    Delotte, Jerome
    Arias, Tatiana
    Guerin, Olivier
    Boulahssass, Rabia
    Bereder, Isabelle
    Bongain, Andre
    Benchimol, Daniel
    Bereder, Jean Marc
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2015, 94 (04) : 435 - 439
  • [30] Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer
    Carrabin, N.
    Mithieux, F.
    Meeus, P.
    Tredan, O.
    Guastalla, J. -P.
    Bachelot, T.
    Labidi, S. I.
    Treilleux, I.
    Rivoire, M.
    Ray-Coquard, I.
    BULLETIN DU CANCER, 2010, 97 (04) : E23 - E32
12345